- Open Access
Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule
Critical Care volume 13, Article number: R54 (2009)
To identify risk factors for early (< three days) intensive care unit (ICU) admission of patients hospitalised with community-acquired pneumonia (CAP) and not requiring immediate ICU admission, and to stratify the risk of ICU admission on days 1 to 3.
Using the original data from four North American and European prospective multicentre cohort studies of patients with CAP, we derived and validated a prediction rule for ICU admission on days 1 to 3 of emergency department (ED) presentation, for patients presenting with no obvious reason for immediate ICU admission (not requiring immediate respiratory or circulatory support).
A total of 6560 patients were included (4593 and 1967 in the derivation and validation cohort, respectively), 303 (4.6%) of whom were admitted to an ICU on days 1 to 3. The Risk of Early Admission to ICU index (REA-ICU index) comprised 11 criteria independently associated with ICU admission: male gender, age younger than 80 years, comorbid conditions, respiratory rate of 30 breaths/minute or higher, heart rate of 125 beats/minute or higher, multilobar infiltrate or pleural effusion, white blood cell count less than 3 or 20 G/L or above, hypoxaemia (oxygen saturation < 90% or arterial partial pressure of oxygen (PaO2) < 60 mmHg), blood urea nitrogen of 11 mmol/L or higher, pH less than 7.35 and sodium less than 130 mEq/L. The REA-ICU index stratified patients into four risk classes with a risk of ICU admission on days 1 to 3 ranging from 0.7 to 31%. The area under the curve was 0.81 (95% confidence interval (CI) = 0.78 to 0.83) in the overall population.
The REA-ICU index accurately stratifies the risk of ICU admission on days 1 to 3 for patients presenting to the ED with CAP and no obvious indication for immediate ICU admission and therefore may assist orientation decisions.
Approximately 10% of patients hospitalised for community-acquired pneumonia (CAP) are admitted to an intensive care unit (ICU), and these patients account for about 10% of all medical admissions to ICUs [1, 2]. Although some patients with CAP have an obvious reason for ICU admission on the day of presentation to the emergency department (ED), a substantial proportion of others will develop organ failure within a few days . Transfer to the ICU for delayed respiratory failure or delayed onset of septic shock is associated with increased mortality . Hence, a major challenge in the management of CAP is to identify patients at risk for rapidly developing adverse medical outcomes among those presenting to the ED with no obvious reason for immediate ICU admission.
Since the publication of the American Thoracic Society (ATS) guidelines in 1993, several prediction rules have been derived to identify ED patients with severe CAP, defined by adverse outcomes (including ICU admission, shock requiring vasopressors, acute respiratory failure requiring mechanical ventilation or death). Most of these prediction rules were derived in populations including patients presenting with an obvious reason for immediate ICU admission. However, a prediction rule is essentially relevant to help management decisions for patients not requiring immediate respiratory or circulatory support at presentation to the ED . Additionally, previous rules were designed to predict endpoints occurring within 30 days of ED presentation, which may be an excessively remote perspective, when considering both the viewpoint of the ED and ICU physicians' orientation decisions, and the potential relatedness of a late ICU transfer to physiological alterations caused by pneumonia itself.
Therefore, our goals were to identify risk factors for ICU admission within three days of hospital stay for patients initially presenting without respiratory failure or shock, and to derive and validate a prediction rule to stratify the risk of ICU admission on days 1 to 3.
Materials and methods
This study was based on data obtained from four prospective, multicentre studies in adults with pneumonia. Two were from North America, the Pneumonia Patient Outcomes Research Team (PORT) cohort study and the Emergency Department Community-Acquired Pneumonia (EDCAP) trial, and the two other cohorts were from Europe (Pneumocom-1 and Pneumocom-2). The methods used for the Pneumonia PORT, EDCAP and Pneumocom studies have been reported previously [6–9]. With the exception of the EDCAP cluster randomised trial, all studies were observational. The study protocols were approved by the institutional review boards of the participating institutions. We received permission to use the data from the four original multicentre studies and the need for informed consent for the specific purpose of this study was waived.
All studies enrolled consenting adults with pneumonia. Nursing home residents with health care-associated pneumonia were not eligible for the current analysis . Additional exclusion criteria (discharge within 7 to 10 days of presentation, positive HIV antibody titre, immunosuppression, history of cystic fibrosis, ventilation via a tracheostomy or chronic use of mechanical ventilation) varied across the four original studies (Additional data file 1). Patients presenting with acute respiratory failure requiring mechanical ventilation (invasive or noninvasive mechanical ventilation) or shock (systolic arterial pressure below 90 mmHg and requiring vasopressors) who were transferred to the ICU on the same day of ED presentation were considered to have an obvious indication for immediate ICU admission  and were excluded from the present analysis. For the purposes of this study, 70% of the patients were randomly assigned to a derivation cohort and 30% to an internal validation cohort.
Baseline data collection
All four studies used physician interviews and standardised reviews of medical records to collect baseline demographic variables, comorbid illnesses, physical examination findings, laboratory test results and radiographic findings. According to previously published algorithms, prediction rules were derived from each patient's baseline data [6, 12, 13]. In accordance with methods used in these previous studies, missing variables were assumed to be normal [14, 15].
The primary outcome measure was the occurrence of ICU admission on days 1 to 3 of ED presentation (Figure 1). The secondary outcome was 28-day all-cause mortality.
Baseline and follow-up characteristics were reported as mean and standard deviation or median and interquartile range for continuous variables, and as percentages for discrete variables. We compared patient baseline characteristics according to ICU admission on days 1 to 3, using the two-tailed t tests or Wilcoxon tests for continuous variables, and chi-squared tests or the Fisher's exact test for discrete variables.
We first developed a parsimonious logistic regression model by removing variables from the full main effects model using a backward approach with a cut-off value of P = 0.10. The variables introduced in the model included demographic characteristics, comorbid conditions and physical, radiographic and laboratory findings. Subsequently, we transformed the regression coefficients of the variables in the final model to an integer value for each variable according to its contribution to the risk estimation. Finally, we derived a four risk class prediction rule for predicting ICU admission on days 1 to 3, and estimated the area under the receiver operating characteristics (ROC) curve for predicting ICU admission on days 1 to 3. We also estimated the area under the ROC curve of our score within each original cohort. All analyses were performed using Stata version 8.0 (Stata Corporation, College Station, TX, USA).
Overall, 6560 patients were retained in our analysis, including 4593 (70%) in the derivation and 1967 (30%) in the validation cohort (Figure 1). The characteristics of the two cohorts are compared in Tables 1 and 2.
During the 28-day follow-up, 378 patients were admitted to an ICU (5.6% and 6.0%, respectively in the derivation and validation cohorts; Table 2). More than 80% of ICU admissions occurred within three days of ED presentation. Conversely, nearly 80% of the 262 deaths occurred after three days, whereas about 20% (53) of the deaths occurred within three days of presentation.
Factors associated with ICU admission on days 1 to 3
Baseline characteristics associated with ICU admission on days 1 to 3
Patients admitted to the ICU on days 1 to 3 were more likely to be elderly men with comorbidities, and to have more vital sign abnormalities (altered mental status, tachypnoea and hypotension), radiographic or laboratory abnormalities (hypoxaemia, hyponatraemia, acidosis, high blood urea nitrogen level, and pleural effusion or multilobar infiltrates; Tables 3 and 4).
Independent risk factors
In multivariable analysis, we identified 11 independent predictors of ICU admission on days 1 to 3, including male gender, age under 80 years and at least one comorbid condition; all other independent risk factors were physical or laboratory findings (Table 5).
Risk of early admission to the ICU
The risk of early admission to the ICU (REA-ICU) score ranged from 0 to 17 and was stratified into four risk classes (REA-ICU index; Table 6). In the derivation cohort the rate of ICU admission on days 1 to 3 ranged from 1.1% for risk class I to 27.1% for risk class IV and 28-day mortality ranged from 1.2 to 15.1%. Similar rates were observed in the validation cohort. In risk class I, five patients (not admitted to ICU) died within three days of ED presentation. The risk class I patients accounted for 2510 of 4593 (54.6%) and 1099 of 1967 (55.9%) patients, respectively, in the derivation and validation cohorts, with 27 out of 2510 (1.1%) and 14 out of 1099 (1.3%) of these patients admitted to the ICU, respectively. Among these 41 patients, 10 were classified as high-risk using the Pneumonia Severity Index (PSI) and none subsequently died.
The area under the ROC curves for the REA-ICU score was 0.80 (95% confidence interval (CI) = 0.77 to 0.83) and 0.80 (95% CI = 0.76 to 0.84) in the derivation and validation cohorts, respectively.
The risk of admission to the ICU on days 1 to 3 increased significantly from risk class I to risk class IV within each of the four original cohorts (P < 0.001 for each cohort). The area under the ROC curve of the score for predicting admission to an ICU on days 1 to 3 ranged from 0.76 (95% CI = 0.72 to 0.90) in the EDCAP cohort to 0.82 (95% CI = 0.85 to 0.90) in the Pneumocom-2 cohort.
The REA-ICU score yielded a higher area under the ROC curve than the PSI (0.75, 95% CI = 0.73 to 0.78), CURB-65 (0.69, 95% CI = 0.66 to 0.72) and Espana Severe CAP (SCAP) (0.74, 95% CI = 0.71 to 0.76) for predicting ICU admission on days 1 to 3 for patients not requiring immediate circulatory or ventilatory support (P < 0.001 for all pairwise comparisons involving the REA-ICU score).
In this study, we identified 11 baseline characteristics that were independently associated with ICU admission on days 1 to 3 in a broad range of patients presenting with CAP and no obvious reason for immediate ICU admission (i.e. not requiring immediate respiratory or circulatory support). These characteristics included male gender, age younger than 80 years, comorbid condition of 1 or higher, tachypnoea, tachycardia, leukopenia or leukocytosis, multilobar infiltrates or pleural effusion, hypoxaemia, acidosis, hyperuraemia and hyponatraemia. From this set of variables, we derived a prediction rule, REA-ICU score, that demonstrated a consistent discriminatory power for predicting ICU admission occurring within three days of ED presentation for patients with CAP not requiring immediate ICU transfer.
The British Thoracic Society advocates using a set of only four variables (CURB-65) and suggests considering ICU referral when three or more criteria are present . The ATS rule, modified in 2001 , appears to have a slightly better predicting accuracy than the CURB-65 or the PSI; however, it still results in a substantial proportion of patients misclassified with regard to ICU admission . Moreover, the two major criteria of the ATS rule – requirements for mechanical ventilation and the occurrence of shock – are obvious reasons for ICU admission. Espana and colleagues derived the SCAP prediction rule that was shown to discriminate better than previous prediction rules between ED patients with and without CAP-related adverse medical outcomes, including 30-day mortality and ICU referral . Narrowing the criteria for severe CAP needing ICU admission to the requirement for intensive respiratory or vasopressor support (IRVS), Charles and colleagues recently developed the SMART-COP, which demonstrated interesting characteristics to predict IRVS requirement during the whole hospital course of patients . We took a different perspective and focused on patients not presenting to the ED with a need for IRVS, but subsequently transferred to the ICU within the first three days of admission; thus, our index might be especially useful for emergency physicians to assess the potential risk of ICU requirement within the next few days among those patients presenting with none of the ATS major severity criteria. As a result, the REA-ICU performed significantly better than existing prediction rules (PSI, CURB-65, Espana SCAP) in predicting ICU admission on days 1 to 3 of ED presentation in these patients.
Indeed, the criteria for inclusion in our analysis have several distinctive features from previous attempts at predicting CAP severity. First, contrasting with previous prediction rules, we focused on the more challenging subgroup of patients presenting with moderately severe CAP and no requirement for immediate ICU admission ; hence, we excluded patients with obvious respiratory or haemodynamic failure at presentation. Indeed, including such clinically apparent features in a prediction rule is likely to improve its operative characteristics, but is of limited value in assisting physicians in triaging patients [19, 20].
Second, we focused on admission to ICU within three days of ED presentation, instead of including all 28-day outcomes. Pneumonia is the most common cause of severe sepsis, and severe CAP should be seized in the overall context of sepsis from pulmonary infection with organ dysfunction(s) potentially requiring intensive care [5, 21]. Indeed, most sepsis-related organ failures in this setting occur early [3, 22]. Accordingly, our findings in a large sample of patients presenting with CAP confirm that admission to ICU mostly occurred within the first three days of ED presentation. In addition, late ICU admissions may be associated with other factors than the severity of pneumonia itself (e.g. decompensated comorbidity or an intercurrent event), and not be influenced by its initial management [23–25]. Moreover, the REA-ICU score was based on data readily available at patient presentation to the ED and did not include results from ED monitoring, which would be less relevant to triaging patients in the ED setting [12, 26]. Accordingly, we could not include laboratory tests that were not evenly collected across the four original studies (e.g. albuminaemia).
Third, we considered that adequate ICU admission should not be restricted to patients requiring IRVS . Indeed, ICU care has been demonstrated to improve outcome in severely ill and unstable patients, and these patients require intensive monitoring and may potentially need immediate intervention . Therefore, given the characteristics of the REA-ICU (Additional data file 2), we suggest that intensive care physicians be informed of those patients with the highest risk of three-day ICU admission. This could be achieved by requesting the advice of an intensivist for such patients, who would then help decide on the most appropriate site of care for providing them adequate management and close monitoring, possibly in the ICU or an intermediate-care unit as deemed appropriate.
Fourth, despite substantial differences across the four original cohorts in patient characteristics and outcomes (Tables 1 and 2) [6–9], the overall discriminatory power of the REA-ICU score in predicting ICU admission on days 1 to 3 was quite high across the four original cohorts, reflecting the robustness of this score .
Several potential limitations of our study must be acknowledged. First, there were slight methodological differences and exclusion criteria across the four cohorts analysed. However, the definitions used in EDCAP, Pneumocom-1 and Pneumocom-2 were all based on the Pneumonia PORT study. Second, our findings do not take into account processes of care or causative pathogens, which may have confounded the relation between risk class and patient outcomes. As these data were not collected in a standardised manner across the four studies, we could not adjust for these variables. Third, the REA-ICU score includes 11 variables, which might limit its applicability to clinical use. However, the 20-variable PSI has been successfully implemented in various settings, including routine practice [7, 9, 29–31]. Fourth, our findings are based solely on hospital admission data and patient monitoring data were not recorded during the initial hospital course, so we could not analyse the adequacy of secondary ICU admission (e.g. requirement for mechanical ventilation or vasopressor, or other reason for ICU admission). Fifth, all laboratory tests were performed at the discretion of the attending physicians and missing values were assumed to be normal. This strategy is widely used in the clinical application of prediction rules and reflects the methods used in the original derivation and validation of the PSI . Indeed, patients with less severe illness were more likely to have missing values for laboratory findings. Finally, prediction scores often perform better in their derivation and internal validation cohorts than in external validation studies; therefore, external independent validation is required.
In summary, using a large database combining four prospective cohorts of patients with CAP, we derived and validated the REA-ICU index to predict ICU referral within the first three days of hospital admission in patients without overt circulatory or respiratory failure at ED presentation. This index demonstrates valuable characteristics for stratifying the risk of admission to ICU on hospital days 1 to 3. Using this combination of variables might help ED physicians to more accurately assess the potential need for ICU admission in the challenging group of high-risk patients presenting with no obvious reason for ICU admission [5, 32, 33].
Among 6560 patients with CAP and no obvious indication for ICU admission at ED presentation, 303 (4.6%) were admitted to the ICU within the three following days.
Eleven variables – male gender, older age, comorbid conditions, tachypnoea, tachycardia, multilobar infiltrate or pleural effusion, low or high white blood cell count, hypoxaemia, high blood urea nitrogen, acidosis, hyponatraemia – were independently associated with admission to ICU on days 1 to 3, and were used to derivate the REA-ICU index.
The REA-ICU index stratified ED patients with CAP and no obvious indication for ICU admission into four classes of risk for ICU admission on days 1 to 3, ranging from 0.7 to 31%. This index might help ED physicians and intensivists in the disposition decision.
American Thoracic Society
Emergency Department Community-Acquired Pneumonia
intensive care unit
intensive respiratory or vasopressor support
Patient Outcomes Research Team
Pneumonia Severity Index
risk of early admission to ICU
receiver operating characteristics
severe community-acquired pneumonia.
Valles J: Severe pneumonia: sources of infection and implications for prevention. Sepsis 1998, 1: 199-209. 10.1023/A:1009789309879
Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD: Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985, 10: 204-210. 10.1016/S0163-4453(85)92463-6
Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC: Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest 2006, 129: 968-978. 10.1378/chest.129.4.968
Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, Beaucaire G: A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995, 21: 24-31. 10.1007/BF02425150
Huang DT, Yealy DM: Decision rules and pneumonia: What are we "predicting", and for whom? Am J Respir Crit Care Med 2006, 174: 1169-1170. 10.1164/rccm.200609-1389ED
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336: 243-250. 10.1056/NEJM199701233360402
Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, Moritz F, Cibien JF, Guerin T, Carre E, Lafontaine A, Bertrand MP, Santin A, Brun-Buisson C, Fine MJ, Roupie E, Pneumocom Study Investigators: Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007, 44: 41-49. 10.1086/509331
Renaud B, Coma E, Hayon J, Gurgui M, Longo C, Blancher M, Jouannic I, Betoulle S, Roupie E, Fine MJ: Investigation of the ability of the Pneumonia Severity Index to accurately predict clinically relevant outcomes: a European study. Clin Microbiol Infect 2007, 13: 923-931. 10.1111/j.1469-0691.2007.01772.x
Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, Fine JM, Obrosky DS, Mor MK, Whittle J, Fine MJ: Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005, 143: 881-894.
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 2005, 171: 388-416. 10.1164/rccm.200405-644ST
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America, American Thoracic Society: Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007,44(Suppl 2):S27-72. 10.1086/511159
Espana PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM: Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006, 174: 1249-1256. 10.1164/rccm.200602-177OC
Lim WS, Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58: 377-382. 10.1136/thorax.58.5.377
Sirio CA, Shepardson LB, Rotondi AJ, Cooper GS, Angus DC, Harper DL, Rosenthal GE: Community-wide assessment of intensive care outcomes using a physiologically based prognostic measure: implications for critical care delivery from Cleveland Health Quality Choice. Chest 1999, 115: 793-801. 10.1378/chest.115.3.793
Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, Graff LG, Fine JM, Fine MJ: Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005, 118: 384-392. 10.1016/j.amjmed.2005.01.006
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163: 1730-1754.
Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN: Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002, 166: 717-723. 10.1164/rccm.2102084
Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Australian Community-Acquired Pneumonia Study Collaboration, Grayson ML: SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008,47(3):375-384. 10.1086/589754
Ewig S: Against misleading predictions for severe community-acquired pneumonia. Am J Respir Crit Care Med 2007, 175: 289. Author reply 289–290.
Sox HC: Medical decision making. Boston: Butterworths; 1988.
Wang HE, Shapiro NI, Angus DC, Yealy DM: National estimates of severe sepsis in United States emergency departments. Crit Care Med 2007, 35: 1928-1936. 10.1097/01.CCM.0000277043.85378.C1
Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274: 968-974. 10.1001/jama.274.12.968
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004, 30: 536-555. 10.1007/s00134-004-2398-y
Osborn TM, Nguyen HB, Rivers EP: Emergency medicine and the surviving sepsis campaign: an international approach to managing severe sepsis and septic shock. Ann Emerg Med 2005, 46: 228-231. 10.1016/j.annemergmed.2005.04.007
Shapiro NI, Howell MD, Talmor D, Lahey D, Ngo L, Buras J, Wolfe RE, Weiss JW, Lisbon A: Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med 2006, 34: 1025-1032. 10.1097/01.CCM.0000206104.18647.A8
Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A: Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998, 158: 1102-1108.
Guidelines for intensive care unit admission, discharge, and triage. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine Crit Care Med 1999, 27: 633-638. 10.1097/00003246-199903000-00048
Justice AC, Covinsky KE, Berlin JA: Assessing the generalizability of prognostic information. Ann Intern Med 1999, 130: 515-524.
Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG: A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000, 283: 749-755. 10.1001/jama.283.6.749
Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, Halm EA, Singer DE: Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998, 158: 1350-1356. 10.1001/archinte.158.12.1350
Carratala J, Fernandez-Sabe N, Ortega L, Castellsague X, Roson B, Dorca J, Fernandez-Aguera A, Verdaguer R, Martinez J, Manresa F, Gudiol F: Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005, 142: 165-172.
McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS: Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 2000, 284: 79-84. 10.1001/jama.284.1.79
Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, Le Gall JR, European Sepsis Study Group: Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 2005, 171: 461-468. 10.1164/rccm.200403-324OC
This study was funded by the "Direction de la Recherche Clinique d'Ile de France" as part of the "Programme Hospitalier de Recherche Clinique" (Grant N°AOM 89-145).
BR was supported by the "Département de la Formation Continue des Médecins de l'Assistance Publique des Hôpitaux de Paris (AP-HP)", by l'ARMUR (Association de Recherche en Médecine d'Urgence, Henri Mondor, Créteil) France, by AQUARE (Association pour la QUAlité, la Recherche et l'Enseignement à l'Hôpital Saint-Joseph (Paris)), and by GlaxoSmithKline France.
JL was supported by a grant from the Egide Foundation (French Foreign Office, Programme Lavoisier) and by Grenoble university hospital (Direction de la Recherche Clinique).
Participants in the Pneumocom study group made substantial contributions to acquisition of data. Dr Laurent Delaire and Dr Sylvie Betoulle (Centre Hospitalier Général d'Angoulême), Dr Philippe Grippon (Centre Hospitalier Général de Fontainebleau), Dr Jean François Cibien, Dr Cécile Noyez and Dr Pierre Mardegan (Centre Hospitalier Général de Montauban), Dr Alain Cannamela, Dr Thomas Guérin and Dr Emmanuelle Fritsch (Centre Hospitalier Général de Roanne), Dr Jean-Pierre Bal and Dr Marie-Pierre Bertrand (Centre Hospitalier Inter-Communal de Créteil), Dr Nicolas Simon and Luce Guérin (Centre Hospitalier Inter-Communal de Poissy-Saint-Germain-en-Laye), Dr Jérôme Khazakha and Dr Lafontaine (Centre Hospitalier Inter-Communal de Tarbes), Dr Didier Jan and Dr Emmanuel Carre (Centre Hospitalier Régional de Vannes), Dr Isabelle Claude, Dr Moulin and Dr Gilles Mehu (Centre Hospitalier de Quimper, Quimper, France), Dr Alain Delhumeau, Dr Pierre Marie Roy and Dr Betty Mazet (Centre Hospitalier Universitaire d'Angers), Dr Dominique Pateron and Dr Joelle Benkel (Centre Hospitalier Universitaire de Bondy), Dr Françoise Carpentier, Dr Marc Blancher and Dr Caroline Douchant (Centre Hospitalier Universitaire de Grenoble), Dr Gilles Potel, Dr Philippe Leconte and Dr Celine Longo (Centre Hospitalier Universitaire de Nantes), Dr Jean Rouffineau and Dr Hélène Boureaux (Centre Hospitalier Universitaire de Poitiers), Dr Jacques Bouget, Dr Isabelle Jouannic and Dr Marie-Hélène Marquez (Centre Hospitalier Universitaire de Rennes), Dr Muller, Dr Fabienne Moritz, Dr Joël Jenvrin and Dr Iliasse Idrissi (Centre Hospitalier Universitaire de Rouen), Dr Hervé Jérôme, Dr Alfred Ngako, Dr Marie-Jeanne Calmette, Dr Virginie Lemiale, Dr Marie Debacker and Dr Cyril Boraud (Centre Hospitalier Universitaire Henri Mondor, Créteil), Dr Guillermo Vazquez-Mata (Hospital de Sant Pau, Barcelona), Dr Joseph Gomez and Josep Solis (Hospital Nostra Senyora de Meritxell, Andorra), Dr Sara Graell, Sngels Lamarca and Antonia Lopez (Hospital de Terrassa), Dr Josep Alba and Francesc Chavales (Hospital de l'Alt Penedes, Vilafranca), Dr Mireia Ferrer and Montserrat Costa (Hospital Municipal de Badalona), Dr Carme Agusti and Santi Tomas (Hospital Mutua de Terrassa), Dr Antoni Ayuso and Esther Costa (Clinica Platon, Barcelona), Dr Carles Ferré and Imma Sanchez (Funadació Sanitària d'Igualada), Dr Hisao Onaga and Angel Garcia (Hospital Josep Trueta, Girona), Dr Marina Gomez and Anna Coll (Hospital d'Olot), Dr Joseph Lluis Tricas and Francesc Xavier Altimiras (Hospital de Mollet), Dr Sonia Vega and Carles Sardà (Hospital de Figueres), Dr Oscar Len (Hospital Vall D'Hebró, Barcelona), Dr Gemma Vidal and Josep Font (Consorci Sanitari del Parc Taulí, Sabadell).
MJF consults for the University of Pennsylvania and GeneSoft Pharmaceuticals Inc. He also receiveds honoraria from Zynx Health Corporation, STA Healthcare Communications Inc., University of Alberta and Maine Medical Center). MJF gives expert testimony for Stephen Lynn Klein, Kellogg & Siegelman, Swanson, Martin, & Bell, William J. Burke, Chad McGowan, Chernett, Wasserman, Yarger and Pasternak, LLC. MJF received grants from Pfizer Inc. BR received grants from GlaxoSmithKline Inc. MJF also received royalties from Up-to-Date.
BR, JL, CBB made substantial contributions to conception and design. BR, JL, EC, AS, MG, NC, ER, FH, JH, MS, MJF and CBB made substantial contributions to acquisition of data. BR, JL, EC, AS, NC, MS, MJF and CBB made substantial contributions to analysis and interpretation of data. BR, JL, EC, AS, MG, MJF, FH, JH and CBB were involved in drafting the manuscript or revising it critically for important intellectual content. BR, JL, EC, AS, MG, NC, ER, FH, JH, MS, MJF and CBB gave their final approval of the version to be published. BR, EC, AS, MG, ER, JH, MS and MJF were involved in acquisition of funding and collection of data. BR, EC, AS, MG, MJF and CBB were involved in general supervision of the research group.
Electronic supplementary material
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Renaud, B., Labarère, J., Coma, E. et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care 13, R54 (2009). https://doi.org/10.1186/cc7781
- Intensive Care Unit
- Intensive Care Unit Admission
- Additional Data File
- Validation Cohort
- Prediction Rule